Protection of the hydroxyl group at the C-5 position of milbemycin A4 and D was carried out to investigate the influence of the C-5 hydroxyl group on the anthelmintic potency of these derivatives. Moreover, the hydroxyl group was converted into amide groups as bioisosters. Biological activities of these derivatives were measured against Nippostrongylus brasiliensis in vitro, and minimal concentrations which induce 100% immotility in wormsweredetermined for each derivative.
Biological testing revealed that the hydroxyl group at C-5 is a structural requirement for retaining anthelmintic activity.
The milbemycins (1) are a family of 16-membered ring macrolides isolated from Streptomyces hygroscopicus subspecies aureolacrimosus1~3\ Shortly after the discovery of the milbemycins, a Merck group reported on the isolation of the avermectins (2) from Streptomyces avermitilis4 '5) .
These two families of compounds possess similar structures as illustrated in Fig. 1 , and exhibit exceptionally potent acaricidal and insecticidal activities. Although a macrocyclic lactone structure is one of the features in the antibacterial macrolides and the antifungal macrocyclic polyenes, the avermectins and the milbemycins have surprisingly neither antibacterial nor antifungal activities. Since their discovery, the avermectins and the milbemycins have attracted considerable interest from several laboratories due to their potent activities and unique structures6~9). Furthermore numerous efforts have been madeto develop naturally occurring compounds,or semisynthetic derivatives, as insecticides for agricultural use and as anthelmintics for not only animal but also humanuse. Presently some avermectins and milbemycins are in commonuse for three particular applications. They are as follows: a combination of the 22,23-dihydro derivatives of avermectin Bla and Blb is effective as a veterinary endectocide, a mixture of milbemycin A4 and A3 as an agricultural miticide, and a combination of the oxime derivatives of milbemycin A4 and A3 as a canine parasiticide.
In the course of our program to develop an anthelmintic, we have investigated chemical transformations of milbemycins. The biochemical explanation as to whythe avermectins and the milbemycins possess such activities is based on the argument that they interfere with the neurotransmission of invertebrates by their allosterical binding to GABA-binding-protein10).
The hydroxyl groups at the C-5 and C-7 positions, the ester moiety, and the oxygen atoms in the spiroacetal moiety of the milbemycin skeleton must have important roles in the formation of this binding complex. Thus one would expect that protection of the hydroxyl groups of the milbemycin skeleton would be disadvantageous for the biological activities. However, many derivatives of avermectins and milbemycins have been synthesized by protecting the C-5 hydroxyl group with a proper functional group. These manipulations are due to the notion that the activities in vivo are influenced by variations in uptake and metabolism of the individual compounds.In our laboratories, a vitro assay which excludes the effects of uptake and metabolism has been used to examine the biological effect which those potent derivatives have. In this paper, we will describe the chemical transformations performed at the C-5 position of milbemycin A4 and D, and their biological activities in this assay system.
Results and Discussion
Initially, we synthesized derivatives varying in functionality, namely esters, ethers, sulfonates and carbamates of the C-5 hydroxyl group, by standard chemistry as described in Scheme 1 1 1}. The synthesized derivatives and the parent compounds, milbemycin A4 and D, were examined their potencies on N. brasiliensis motility in vitro, i.e. minimal concentrations required to cause 100% of immotile worms after 24hours of incubation at 26°C were determined for each milbemycin analog, and the concentrations are described as MEC(/ig/ml) values. As shown in Table 1 , the milbemycin analogs synthesized showed lower activities than the parent compounds. The levels of activities of the derivatives were almost the same in each series ofA4 and D.
Scheme 1. Modifications of the C-5 hydroxyl group of milbemycins. As the importance of the C-5 hydroxyl group in the milbemycin skeleton for biological activity became clear, we next focussed on a study of the corresponding bioisosters. Functional groups such as amide, sulfonamide and ureido are well known as the bioisosters for hydroxyl groups12); therefore, the C-5 hydroxyl group was replaced by these functionalities.
Firstly, we examined reductive amination to obtain the 5-amino derivative directly. Thus, the 5-oxomilbemycin A4 (10a), which was easily obtained from milbemycin A4 (la) by the oxidation of the C-5 hydroxyl group with MnO213), was treated with NH4OAc and NaCNBH3in MeOH.The reaction, however, afforded a complex mixture (Equation 1). Consequently, we attempted a somewhatmore elaborate sequence applying double inversion at the C-5 position of milbemycins (la, b). Thus, the C-5 hydroxyl group was inverted by the Mitsunobu reaction (HCO2H, Ph3P, diethyl azodicarboxylate) and subsequent hydrolysis (NaHCO3, H2O-MeOH-THF) of the formate (lla,b) gave hydroxy derivative (12a,b).
Methanesulfonylation (MeSO2Cl, Et3N) of the a-hydroxy derivative yielded a-methanesulfonate (13a, b), which was reacted with NaN3in CH3CNat ambient temperature to give a crude mixture containing 5/?-azido derivative (14a,b). Subsequently, the crude mixture was subjected to the reduction with Zn in DMF including a small amount of H2Oand AcOH.Purification of the reaction mixture by column chromatography gave the desired 5/?-amino derivative (15a,b) in moderate yield (50 and 43%, respectively). Despite only attaining moderate levels of conversion to the amino derivatives, other reaction conditions to obtain these derivatives were not attested further. By reaction with Ac2O, MeSO2Cl or MeNCO, the amino derivatives were converted into their corresponding acetamides (16a, b), methanesulfonamides (17a, b) or ureido derivatives (18a, b) in good yields (Scheme 2). FEB. 1994 Scheme 2. Synthesis of 5-amino milbemycin derivatives.
The results of the aforementioned biological test of the bioisosters and intermediates synthesized are described in Table 2 . Contrary to our expectations, these bioisosters (16, 17 and 18) required even higher concentrations than their corresponding precursors to induce full immotility in worms. Furthermore, their activities were lower than those of the O-protected derivatives as shownin in the bioisosters seemed to interfere with the binding to the receptor rather than act as bioisosters for the hydroxyl group. On the other hand, a-substituted derivatives were anticipated to have lower activities than /?-substituted derivatives bacause the conformation and the shape of the milbemycinskeleton would be modified by the introduction of the a-substituent.
Actually, the a-formyloxy derivatives (lla, b) and the a-hydroxy derivatives (12a, b) showed much lower activities than the^-substituted derivatives in Table 1 . However, the a-methanesulfonyloxy derivatives (13a, b) showed nearly the same activities as those of the^-substituted derivatives as shown in Table 1 , and even higher than the corresponding /?-substituted sulfonates. Although the interpretation of these results were not in accord with the objective of this study, it is nonetheless an interesting one.
In conclusion, ethers, esters, sulfonates and carbamates of the C-5 hydroxyl group of milbemycin A4 and D were synthesized as a means of masking the hydroxyl functionality. Furthermore amide functionalities as bioisosters were introduced into the C-5 position of the skeleton in place of the hydroxyl group. All derivatives synthesized were tested for their potencies on N. brasiliensis motility in vitro. Unfortunately, there were no derivatives which exhibited a higher biological activity than the parent milbemycin A4 or D in our investigations. It was confirmed that the existence of the /Miydroxyl group at the C-5 position is essential for the preservation of the potent biological activities of the milbemycins.
Expe riment al
N. brasiliensis Motility Assay
The wormsused were the N. brasiliensis L3 stage. The assay were conducted as follows: About 30 worms were suspended in the phosphate buffer solution (0.90 ml, pH 7.6) containing 1 %of sterilized Bacto ager (DIFCO) in each test tube. The milbemycin analogs tested were dissolved in polyethylene glycol 400 (0.10ml) and added to the test tubes containing the worms. After 24hours of incubation at 26°C, the percentage of immotile wormswas determined at several concentrations of each milbemycin analog. The minimal concentration caused 100% of immotile worms was described as a MEC(/zg/ml) value.
General Methods
The natural products (milbemycin A4 and D) were used as starting materials. Each compound was purified by column chromatography before the reactions and showed >96% purity by HPLCanalysis. All compounds were characterized by NMRspectra on a JEOLGSX400 or JEOLGX270 spectrometer in CDCI3solution with tetramethylsilane as internal reference, by mass spectra on a JEOLJMS-AX505H model and by IR spectra on a JASCOFT/IR-830 and were in full agreement with the assigned structures. Unless otherwise indicated all common reagents and solvents were used as obtained from commercial FEB. 1994 suppliers without further purification.
5-0-Methylmilbemycin A4 (3a) To a stirred solution of milbemycin A4 (54mg, O.l mmol) and Ag2O (46mg, 0.2mmol) in CH3CN (0.5 ml) at ambient temperature was added Mel (0.06 ml, l.O mmol) by syringe. After 64 hours, the mixture was filtered with Celite and the filtrate was evaporated in vacuo. 5-0-Acetylmilbemycin A4 (5a) A mixture of milbemycin A4 (108 mg, 0.2mmol), Ac2O(50mg, 0.5mmol) and a catalytic amount of dimethylaminopyridine (DMAP) in CH2C12 (l ml) was stirred at ambient temperature for 2hours. The reaction mixture was poured into saturated NaHCO3 and extracted with CH2C12, and the extract was dried over Na2SO4and concentrated in vacuo. The residue was purified by flash chromatography (SiO2, hexane-EtOAc 
5-O-

5-O-Mesylmilbemycin
A4 (8a) To a stirred solution of milbemycin A4 (32mg, 0.06mmol) and Et3N (12mg, 0.12mmol) in CH2C12 (0.5ml) at 0°C was added methanesulfonic anhydride (21 mg, 0.12mmol) in CH2C12 (0.5ml). After 30minutes at 0°C, the reaction mixture was poured into water and extracted with CH2C12. The extract was dried over Na2SO4and evaporated in vacuo. The residue was purified by flash chromatography (SiO2, hexane-EtOAc 5-O-Methylcarbamoylmilbemycin A4 (9a) A mixture of milbemycin A4 (54mg, 0.1mmol), methyl isocyanate (0.015ml, 0.25mmol) and a catalytic amount of Ph2SnCl2 in CH2C12(l ml) was stirred for 30minutes. The reaction mixture was poured into water and extracted with CH2C12,and the extract was dried over Na2SO4and evaporated in vacuo. The residue was purified by flash chromatography (SiO2, hexane-EtOAc 5-ls/?/-5-0-formylmilbemycin A4 (lla) To a stirred solution of milbemycin A4 (0.53g, 0.97mmol), Ph3P (1.57g, 6.0mmol) and HCO2H (0.28 g, 6.0mmol) in THF (7ml) at ambient temperature was added diethyl azodicarboxylate (DEAD, 1.04 g, 6.0 mmol) in THF(3 ml). After 20 hours, the reaction mixture was concentrated in vacuo to dryness. 5-£/?/-milbemycin A4 (12a) A mixture of 5-67?/-5-O-formylmilbemycin A4 (171 mg, 0.3 mmol) and NaHCO3 (50 mg, 0.6mmol) in MeOH(1 ml), THF (2ml) and H2O (0.1 ml) was stirred at ambient temperature for 8 hours. The reaction mixture was poured into water and extracted with CH2C12.The extract was dried over Na2SO4and evaporated in vacuo. The residue was purified by flash chromatography (SiO2, hexane -EtOAc, 2 : 1) to give 162mg (99%) of 5-e/H-5-0-formylmilbemycin A4: IR (KBr)cm "1 3343, 1738, 1717, 1169, 989 ; MS m/z 542 (M+) C32H46O7; *H NMR (270MHz, CDC13) S 4.03 (1H, brs, 5-H), 3.84 (1H, d , /= 1.5Hz, 6-H). 5-Deoxy-5jg-aminomilbemycin A4 (15a) A mixture of 13a (105mg, 0.17mmol) and NaN3 (55mg, 0.85mmol) in CH3CN (1.7ml) containing a catalytic amount of 18-crown-6 ether was stirred at 40°C for 5 hours. The reaction mixture was poured into water and extracted with EtOAc. The extract was washed with water, dried over Na2SO4and evaporated in vacuo. The residue was dissolved in DMF(2ml), and 2 drops of water and 4 drops ofAcOH were added to the solution. Zinc (56mg, 0.85mmol) was added in some portions to the solution cooled in an ice bath. After the addition, the ice bath was removed and the reaction mixture was stirred at ambient temperature for 1 hour. The insoluble material was removed by nitration, and the filtrate was dissolved in EtOAc, washed with saturated NaHCO3,and water, dried, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, EtOAc-EtOH-Et3N, 20: 1 : 1) to give 46mg (50%) of 5-deoxy-5£-aminomilbemycin A4: IR (KBr)cm "1 3480, 3390, 1732, 1713, 1178, 990 5-Deoxy-5ft-acetammomilbemycin A4 (16a) To a stirred solution of 15a (35mg, 0.06mmol) and Et3N (13mg, 0.13mmol) in CH2C12 (lml) at 0°C was added Ac2O (13 mg, 0.13 mmol) in CH2C12 (0.4ml). After 20minutes at 0°C, the reaction mixture was poured into water and extracted with CH2C12. The extract was dried over Na2SO4 and evaporated in vacuo. The residue was purified by flash chromatography (SiO2, hexane-EtOAc, 2 : 3) to give 36mg (95%) of 5-deoxy-5j8-acetaminomilbemycin A4 as white crystals: mp 168~170°C; IR (KBr)cm " 1 3440, 3390, 1740, 1713, 1663, 1175, 989 5-Deoxy-5jS-acetaminomilbemycin D (16b) According to the procedure for 16a, reaction of 15b (38mg, 0.07mmol), Ac2O (14mg, 0.14mmol) and Et3N (14mg, 0.14mmol 5-Deoxy-5^-methanesulfonylaminomilbemycin A4 (17a) To a stirred solution of 15a (40mg, 0.07mmol) and Et3N (15mg, 0.15mmol) in CH2C12 (0.3ml) at 0°C was added MeSO2Cl(17mg, 0.15mmol) in CH2C12(0.3ml). After 30minutes at 0°C, the reaction mixture was poured into water and extracted with CH2C12.The extract was dried over Na2SO4and evaporated in vacuo. The residue was purified by flash chromatography (SiO2, hexane -EtOAc 5-Deoxy-5j8-methanesulfonylaminomilbemycin D (17b) According to the procedure for 17a, reaction of 15b (56mg, 0.1 mmol), MeSO2Cl(23 mg, 0.2mmol) and Et3N (30mg, 0.3 mmol) gave 54mg (86%) of 5-deoxy-5^-methanesulfonylaminomilbemycin D as white crystals: mp 163-166°C; IR (KBr)cm "1 3498, 3294, 1731, 1713, 1180, 1158, 1010, 997, 984 ; MS m/z 633 (M+) C34H51NSO8; XH NMR (270MHz, CDC13) 3 4.22 (1H, m, 3.94 (1H, d, /=6.3Hz,  6-H), 3 .01 (3H, s, -NHSO2C#3).
5-Deoxy-5/H3-methylureido)milbemycin A4 (18a) To a stirred solution of 15a (40 mg, 0.07 mmol) in CH2C12(0.2ml) at 0°C was added methyl isocyanate (8.4mg, 0.15mmol) in CH2C12(0.2ml). The reaction mixture was stirred at ambient temperature for FEB. 1994 2hours; and poured into water and extracted with CH2C12. The extract was dried over Na2SO4 and evaporated in vacuo. The residue was purified by flash chromatography (SiO2, hexane -EtOAc, 1 : 2) to give 32mg (72%) of 5-deoxy-5£-(3-methylureido)milbemycin A4 as white crystals: mp 189~191°C; IR (KBr)cnT1 3400, 1737, 1714, 1673, 1560, 1165, 991 ; MS m/z 598 (M+) C34H50N2O7; 1H NMR (270MHz, CDC13) S 4.79 (1H, br, 5-H), 3.85 (1H, d, /=5.9Hz, 6-H), 2.80 (3H, d, /=5.3Hz, -NHCONHC/73).
5-Deoxy-5j5-(3-methylureido)milbemycin D (18b) As according to the procedure for 18a, reaction of 15b (40mg, 0.07mmol) and methyl isocyanate (12mg, 0.21 mmol) gave 43 mg (97%) of 5-deoxy-5jS-(3-methylureido)milbemycin D: mp 185~190°C; IR (KBr)cm -1 3380, 1694, 1648, 1562, 1523, 1181, 1164, 1010,998; MSm/z612(M+) C35H52N2O7;^NMR (270MHz, CDCI3) S 4.77 (1H, br, 5-H), 3.85 (1H, d, /=5.9Hz,  6-H), 2.80 (3H, brs, -NHCONHCi/3).
